The startup develops a biotechnology research platform that utilizes a proprietary Fragment-Based Drug Discovery (FBDD) engine to identify and match tumor-selective E3 ligases with cancer target proteins. This technology enables the creation of targeted protein degraders, providing effective treatment options for difficult-to-treat cancers and other intractable diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery methods often struggle to address difficult-to-treat cancers and other intractable diseases due to a lack of effective and targeted treatment options. Identifying tumor-selective E3 ligases and matching them with cancer target proteins remains a significant challenge.
Solution
This startup offers a biotechnology research platform leveraging a proprietary Fragment-Based Drug Discovery (FBDD) engine. The platform is designed to identify and match tumor-selective E3 ligases with specific cancer target proteins. This matching process facilitates the creation of targeted protein degraders, offering a novel approach to treating cancers and other diseases that are typically difficult to address with conventional methods. By selectively degrading target proteins within cancer cells, the platform aims to provide more effective and less toxic treatment options.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions focused on developing new cancer therapies and treatments for other intractable diseases.
Features
- Proprietary Fragment-Based Drug Discovery (FBDD) engine for identifying novel E3 ligase-target protein pairs.
- Computational algorithms for predicting E3 ligase selectivity and binding affinity.
- High-throughput screening assays to validate E3 ligase-target protein interactions.
- Chemical synthesis capabilities for generating targeted protein degraders.
- In vitro and in vivo models for evaluating the efficacy and safety of protein degraders.